NSTLShandongPeople’s Republic of ChinaAs iaAntineoplastic Monoclonal AntibodiesAntineoplasticsBioinformaticsBiote chnologyCyborgsDrugs and TherapiesEmerging TechnologiesGeneticsHER2 In hibitorsHealth and MedicineImmunologic AgentsInformation TechnologyMachi ne LearningMedical DevicesMonoclonal AntibodiesPharmaceuticalsTrastuzuma b TherapyTyrosine Kinase Inhibitors
2024
